CloudMD Turns To Public Sector For “Revenue Diversification”
After a series of M&A, CloudMD Software & Services Inc. (TSXV: DOC) seems to be looking now at the public
Read more
Healthcare
Cognetivity Neurosciences Signs Commercial Deal With Dubai Health Authority
Cognetivity Neurosciences (CSE: CGN) continues to expand the deployment of its Integrated Cognitive Assessment, or ICA. The firm this morning
Read more
Datametrex Begins Beta Testing Medi-Call App
Datametrex AI (TSXV: DM) is taking the next step with its telehealth app. The firm this morning announced that is
Read more
Chinese Medical Manufacturer Meihua International Prices Downsized US$36 Million Nasdaq IPO
Chinese disposable medical devices manufacturer Meihua International Medical Technologies Co. (Nasdaq: MHUA) announced on Wednesday the pricing of its initial
Read more
Well Health Digs For Positive News, Highlights Subsidiary Revenues Worth 0.9% Of Current Run Rate
Well Health (TSX: WELL) was apparently itching to put out news this morning. That much is evident, based on the
Read more
CloudMD Announces Immediate Resignation Of CFO For Personal Reasons
CloudMD (TSXV: DOC) this morning announced the transition of its chief financial officer, Daniel Lee. In the interim, the firms
Read more
Cognetivity Signs Commercial Agreement With Emirates Health Services Of UAE
Cognetivity Neurosciences (CSE: CGN) has entered the mainstream. The company this morning announced that it has signed a commercial agreement
Read more
Cognetivity Enters Distribution Arrangement For Dementia Product In Middle East
Cognetivity Neurosciences (CSE: CGN) is expanding its global distribution. The firm this morning announced it has signed a distribution agreement
Read more
CloudMD To Conduct Review On VisionPros Purchase Following Receipt Of Claims
It appears that CloudMD’s (TSXV: DOC) $60 million acquisition of VisionPros last year is already causing the company some headache.
Read more
Therma Bright Expects Rapid Antigen Saliva Test Study To Conclude This Month
Therma Bright (TSXV: THRM) this morning provided a brief update to investors on the status of its clinical study. The
Read more